📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 16:22
6 analysed today
FollowTelegram
6
Today
149,945
All-time analysed
42,987
Positive
6,669
Negative
91,580
Neutral
8,641
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Omkar Pharmachem Reports Rs 1.00 Lakh Net Loss in Q1 FY27 on Zero Core Revenue
Omkar Pharmachem reported a net loss of Rs 1.00 Lakh for the quarter ended June 30, 2026, swinging from a profit of Rs 2.66 Lakhs in the same period last year. The company continues to report zero revenue from core operations (Net Sales), relying entirely on 'Other Operating Income' which fell 33.3% YoY to Rs 9.00 Lakhs. Total expenses of Rs 10.00 Lakhs, primarily driven by employee benefits (Rs 5.14 Lakhs), exceeded total income. With a negligible promoter holding of 0.03% and stagnant business activity, the company remains a micro-cap entity with weak fundamentals.
Confidence: HIGH
What changedThe company has transitioned from a marginal profit to a marginal loss on a year-on-year basis due to a decline in other operating income.
Why it mattersThe results confirm a lack of operational business activity, with the company failing to generate any sales from its primary industry (Commodity Chemicals) for several quarters.
Net Loss (Q1 FY27): Rs 1.00 LakhCore Revenue (Net Sales): Rs 0.00Other Operating Income: Rs 9.00 LakhsEmployee Benefit Expenses: Rs 5.14 LakhsPromoter Holding: 0.03%
📅 Short termThe stock is likely to remain stagnant or underperform given the lack of revenue and the shift into a loss-making position.
📈 Long termLimited structural significance unless the company identifies a new revenue stream or undergoes a major corporate restructuring, given the current zero-revenue status.
⚠ Risk flags
- Zero core operating revenue
- Extremely low promoter holding (0.03%)
- Micro-cap liquidity risk
- Negative other equity of Rs 52.82 Lakhs
Key Highlights
Net Loss of Rs 1.00 Lakh for Q1 FY27 compared to a profit of Rs 2.66 Lakhs in Q1 FY26
Zero revenue from core operations (Net Sales) reported for the quarter
Other Operating Income declined by 33.3% YoY to Rs 9.00 Lakhs from Rs 13.50 Lakhs
Total expenses stood at Rs 10.00 Lakhs, slightly up from Rs 9.92 Lakhs in the previous year's quarter
Promoter holding remains extremely low at 0.03% as per latest available context
👀 What to Watch
Investors should note the lack of core business operations and the company's reliance on non-core income to meet administrative expenses. Watch for any management commentary regarding the revival of core chemical business activities.
Omkar Pharmachem Reports Rs 1.00 Lakh Net Loss in Q1 FY27 on Zero Operating Revenue
Omkar Pharmachem reported a net loss of Rs 1.00 Lakh for the quarter ended June 30, 2026, compared to a profit of Rs 2.66 Lakhs in the same period last year. The company recorded zero revenue from operations, with its total income of Rs 9.00 Lakhs derived entirely from other operating sources. Total expenses of Rs 10.00 Lakhs marginally exceeded income, leading to the loss. Given the company's small market cap of Rs 16 Cr and negligible business activity, the financial performance remains stagnant.
Confidence: HIGH
What changedThe company has transitioned from a marginal profit to a marginal loss on a year-on-year basis for the June quarter.
Why it mattersThe lack of core operating revenue (Rs 0) for multiple quarters indicates a dormant or non-functional business model, posing significant risks to long-term viability.
Net Loss (Q1 FY27): Rs 1.00 LakhRevenue from Operations: Rs 0.00Other Operating Income: Rs 9.00 LakhTotal Expenses: Rs 10.00 LakhMarket Cap: Rs 16 Cr
📅 Short termThe stock is likely to remain under pressure or stagnant due to the lack of operational growth and the shift to a net loss.
📈 Long termLimited structural significance unless the company undergoes a major business pivot or capital infusion to restart operations.
⚠ Risk flags
- Zero core operating revenue
- Extremely low business scale
- Micro-cap liquidity risk
- Promoter holding is negligible at 0.03%
Key Highlights
Net loss of Rs 1.00 Lakh in Q1 FY27 vs a profit of Rs 2.66 Lakhs in Q1 FY26
Revenue from operations remained at Rs 0.00 for the quarter
Other operating income declined by 33.3% to Rs 9.00 Lakhs from Rs 13.50 Lakhs YoY
Total expenses stood at Rs 10.00 Lakhs against total income of Rs 9.00 Lakhs
Earnings Per Share (EPS) turned negative to -0.0099 from 0.0264 YoY
👀 What to Watch
Investors should monitor if the company can initiate any core business operations, as it currently functions with zero operational revenue and relies on miscellaneous income.
